Yahoo Finance Nuvilex Inc. Could Obtain FDA Accelerated Approval after Phase 2b Clinical Trial
Nuvilex Inc.’s (OTCQB:NVLX - News) announced it could obtain an accelerated FDA approval of its pancreatic cancer treatment if it can produce the same strong results in an announced Phase 2b clinical trial.
The results were produced in two separate Phase 1/2 trials using the combination of the Cell-in-a-Box(R) technology with the anticancer drug ifosfamide.
A positive press release from the Silver Spring, Md.–based company suggested that "the market may want to start connecting the dots with this international biotech because as Nuvilex releases each piece of its story, the path is leading to more and more impressive hands guiding Cell-in-a-Box(R) and Nuvilex right to the FDA's door. In fact, given pancreatic cancer is so deadly, it could be sooner rather than later that the medical community becomes familiar with the company in one form or another."
According to Nuvilex, it just named Clinical Network Services Pty Ltd (CNS) as its Contract Research Organization (CRO) for late phase trials, the same company that successfully took the Cell-in-a-Box(R) technology combined with ifosfamide through Phase 1 & 2 clinical trials.
To Work With Dr. Daniel Von Hoff
In addition, Nuvilex announced that would be working with Dr. Daniel Von Hoff, a leading figure in pancreatic cancer, to develop its pancreatic cancer and other treatments utilizing its Cell-in-a-Box(R) technology. These are just the latest of several upbeat press releases from the company that is working on optimizing the anticancer effectiveness of cannabinoids.
Gets $2 Million in Initial Funding
On Feb. 24, the company announced that Lincoln Park Capital purchased 8 million in restricted shares of Nuvilex in exchange for an initial $2 million out of $27 million set aside to advance the company's late-phase pancreatic cancer clinical trials.
Over the last year Nuvilex has issued a bevy of positive press releases about how it is positioning itself and recruiting and hiring the top researchers in the medical-marijuana field. But so far, the company has not produced any concrete products or services for the industry. Neville’s cannabis business appears to still be in the developmental stage. Still, it has hired the brain power that eventually could make it a real player.
On Apr. 18, NVLX’s share price closed at 35 cents, up 7 cents from its close of 28 cents the previous day.
Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:
http://www.pennypickalerts.com
Doctor Orders Showcasing Tranzbyte Corp.’s New Marijuana Dispensers
In other news, Tranzbyte Corp. (OTCPINK:ERBB - News) announced that its recently unveiled automated marijuana dispensing machine, the ZaZZZ American Green Machine, will find homes at some of Colorado's most popular dispensaries - Doctors Orders
According to Stephen Shearin, Tranzbyte's chief operating officer, "We are readying the first of several American Green ZaZZZ automated machines resulting from last week's unveiling in Avon, CO on Apr. 12, and it will be placed at the Doctors Orders Denver dispensary. We are very happy to be working with one of Colorado's premier medical and adult-use marijuana dispensary groups."
Doctors Orders' President Josh Bartch added, "I believe that the ZaZZZ American Green Machine will fit perfectly in our environment and can be easily and securely operated by our customers. I'm very excited that we will be the first dispensary in Denver to use what we believe will be a revolutionary machine."
New Online Marijuana Publication
This is just the latest news from the Tempe, Ariz.-based company. On Apr. 3, it launched American GreenZine, an online publication it’s designed to report on the legal-marijuana industry, from the grower and consumer’s perceptive.
According to Tranzbyte, the new online magazine will use real-time web activity of topical influencers to surface the best content on any subject. The American GreenZine publication is scheduled to begin operating Fri., Apr.
On Apr 18, ERBB’s share price closed at 6 cents, unchanged from closing price of the previous day, on volume of 200.8 million shares.
Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:
http://www.pennypickalerts.com
mCig Inc.’s Unveils New VitaCig Comprised of Vitamins and Natural Supplements
Meanwhile, Bellevue, Wash./Australian e-cigarette maker mCig, Inc. announced Apr. 15 that its wholly owned subsidiary VitaCig, Inc. has officially launched its flagship product: "VitaCig."
The VitaCig is an innovative $2 device that is nicotine-free and smokeless. Instead of harmful toxins, the VitaCig emits flavorful vapor comprised of vitamins, natural supplements, and organic flavors. The VitaCig experience is unique and encompasses everything you love (or loved) about smoking without the things you don't. No tobacco smoke or cigarette smell. No more harmful tar, and no nicotine, just vitamins and flavored vapor delivered in a sleek metallic casing that looks and feels like an eCig.
The VitaCig comes in three great flavor combinations: Relax, Refresh, and Energize.
On Apr. 18, MCIG’s share price closed at 56 cents, up 2 cents from the share price of 54 cents the previous day, on volume of 1,964,716 shares.
Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:
http://www.pennypickalerts.com
ECEM Salzburg Energy places 3,000-Ton Order with Vega Biofuels
Finally, Vega Biofuel, Inc. (OCTPINK:VGPR - News) stock volume surged Apr. 18, with 86,820,461 shares changing hands, significantly higher than its three-month average volume of 68,744,688 shares.
The uptick in volume is being triggered in part by the Norcross, Ga.-based biofuel company’s Apr. 16 announcement that it has received a 3,000-ton order from ECEM Salzburg Energy and Environment Consulting GMGH, which will be the initial Bio-coal order produced at Vega's Joint Venture torrefaction manufacturing facility, ATP-SC, LLC in Allendale, SC.
The Bio-coal will be shipped from the Port of Savannah to The Port of Rotterdam in the Netherlands upon completion.
Vega recently announced that along with its partners, including Agri-Tech Producers, LLC (ATP), is building a state of the art torrefaction facility in Allendale, SC. ATP-SC, LLC will produce various torrefied products, including Bio-coal. The Joint Venture partners plan to build additional plants around the world and the Allendale pilot plant will be a model for those plants.
"We have been working with ECEM for a long time and we are proud to receive a firm order for our Bio-coal product," stated Michael K. Molen, Chairman/CEO of Vega Biofuels, Inc.
On Apr. 18, VGPR’s share price closed at 1 cent, unchanged from its closing price of the previous day.
Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:
http://www.pennypickalerts.com
ABOUT US:
Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.
Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.pennypickalerts.com
Disclosure
Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.
